MAGE-1 (62-70)

MAGE-1 (62-70) is a synthetic peptide fragment derived from the melanoma-associated antigen 1 (MAGE-1) protein, comprising amino acids 62 to 70 of the native sequence. As a member of the MAGE family, this peptide is of significant interest in the field of tumor immunology and antigen presentation studies due to its role as a defined epitope recognized by cytotoxic T lymphocytes. Its sequence specificity and immunogenic properties make it a valuable molecular tool for researchers investigating antigen processing, immune recognition, and the mechanisms underlying tumor-associated antigenicity. The precise synthetic nature of MAGE-1 (62-70) enables reproducible experimental conditions and facilitates a range of applications in peptide-based research.

Antigen presentation studies: MAGE-1 (62-70) is widely utilized in research focused on the mechanisms of antigen processing and presentation by major histocompatibility complex (MHC) class I molecules. By serving as a defined peptide epitope, it allows for the detailed analysis of peptide loading, MHC binding affinity, and subsequent recognition by T cell receptors. This supports investigations into the molecular determinants of immune surveillance and the specificity of cellular immune responses against tumor-associated peptides.

T cell activation assays: The peptide is frequently employed in functional assays designed to evaluate the activation, proliferation, and cytotoxic potential of antigen-specific CD8+ T lymphocytes. By pulsing antigen-presenting cells with MAGE-1 (62-70), researchers can assess T cell receptor engagement, cytokine production, and the efficiency of immune effector responses. Such studies provide critical insights into the immunogenicity of tumor antigens and the cellular mechanisms that drive anti-tumor immunity.

Epitope mapping and immunogenicity profiling: MAGE-1 (62-70) serves as a reference peptide for mapping T cell epitopes within the MAGE-1 protein and related antigenic sequences. Through comparative analyses, scientists can delineate the minimal recognition motifs required for immune activation and characterize the immunodominance hierarchy among overlapping peptides. This facilitates the rational design of peptide-based immunogens and the identification of candidate epitopes for further study.

Peptide-MHC binding analysis: The defined sequence of this peptide enables its use in quantitative binding assays to measure the affinity and stability of peptide-MHC class I complexes. Such studies contribute to a deeper understanding of peptide selection by MHC molecules and the factors influencing antigen presentation efficiency. The data generated can inform computational models of peptide-MHC interactions and support the development of predictive algorithms for epitope selection.

Peptide-based assay development: MAGE-1 (62-70) is also employed as a model peptide in the optimization and validation of immunological assays, such as enzyme-linked immunospot (ELISPOT), flow cytometry-based tetramer staining, and cytotoxicity assays. Its well-characterized immunogenic properties make it a robust standard for calibrating assay sensitivity and specificity, thereby enhancing the reliability of experimental results in studies of cellular immune responses.

1. Identification, Localization in the Central Nervous System and Novel Myostimulatory Effect of Allatostatins in Tenebrio molitor Beetle

2. Tachykinin-related peptides modulate immune-gene expression in the mealworm beetle Tenebrio molitor L

3. Exosomes-mediated Transfer of miR-125a/b in Cell-to-cell Communication: A Novel Mechanism of Genetic Exchange in the Intestinal Microenvironment

4. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation

5. Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet